Novartis AG Stock News

3 Reasons Novartis May Be Your Ticket To A Rich Retirement

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

The FDA has granted Orphan Drug Designation to Novartis AG's (NYSE: NVS) NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer. NIS793 is a fully human anti-TGF-β Ig

Novartis AG ( NVS , Financial) is ahead of the pack of pharma companies developing a new type of cancer treatment that could evolve into a $10 billion market, reported the California News Times.

Novartis CEO Vasant Narasimhan told CNBC there are now lower rates of diagnoses due to reduced hospital visits during the coronavirus pandemic.

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

Novartis CEO Vas Narasimhan joins "Closing Bell" to discuss the company's quarter and demand for theapeutics. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NG

Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your

Novartis AG (NVS) CEO Vas Narasimhan on Q2 2021 Results - Earnings Call Transcript

Novartis AG (NYSE: NVS) boosted its second-quarter core net income by 20% Y/Y to $3.7 billion, beating market expectations as it kept its 2021 guidance. Earnings: The Company posted core EPS of $1

ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Moreho

Several drugmakers have important clinical trial updates on the way.